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imaging findings. Benign prostatic obstruction is diagnosed when obstruction is noted in pressure flow study or uroflowmetry findings, with prostatic enlargement previously noted. Overactive bladder (OAB) syndrome is another common cause of LUTS, which can occur alone or in conjunction with prostatic enlargement; this syndrome is defined as urgency with or without incontinence and is usually associated with frequent urination and nocturia. 8 Detrusor overactivity is a urodynamic observation characterized by spontaneous or provoked involuntary detrusor contractions during the filling phase. 9 Other causes of LUTS include genitourinary cancer, urethral strictures, prostatitis, comorbid conditions, medications, and pelvic trauma or surgery. 10, 11 For these reasons, management of LUTS requires a physician who is knowledgeable about the lower urinary tract.
For the present review article, we conducted a PubMed search using the terms lower urinary tract symptoms, benign prostatic hyperplasia, benign prostatic enlargement, and overactive bladder. Using the search results, we reviewed the evaluation and treatment options for men with LUTS seen in the primary care setting.
Diagnostic Evaluation
The initial evaluation of a man with LUTS begins with a detailed medical history and physical examination focused on the genitourinary system. The history must focus on the nature and duration of the patient's symp- Available data show that ARIs help prevent the progression of BPE and their ability to reduce the risk for acute urinary retention and the need for surgical intervention is statistically significant. 33 They also usually decrease serum PSA levels by 50% within 6 to 12 months; these levels must therefore be multiplied by 2 when they are monitored for the detection of prostate cancer. When LUTS are found to be moderate to severe and bothersome, pharmacotherapy should be initiated.
22,25
The first-line treatment for men with predominant voiding symptoms is generally α-adrenergic receptor antagonists (α-blockers), which work by relaxing the smooth muscle tone and increasing the size of the prostatic lumen during urination. 26 Tamsulosin and silodosin are α 1A selective, whereas terazosin, doxazosin, and alfuzosin are nonselective α 1 -adrenergic receptor blockers. Treatment response is rapid and should be detectible in 7 to 10 days. The most common adverse effects are dizziness, orthostatic hypotension, and retrograde ejaculation. The frequency of α-adrenergic receptor antagonists side effects vary depending on the specific drug. 27 If the symptoms are related to a problem with urinary storage, then a trial of anticholinergics may be indicated.
However, physicians should use caution when prescribing an anticholinergic medication in men with a history of acute urinary retention or elevated postvoid residual volume greater than 250 mL. 22 Oxybutynin, tolterodine, fesoterodine, darifenacin, solifenacin, and trospium are the anticholinergics currently available for the management of OAB. 28, 29 Anticholinergics may exert an effect within 1 week but usually achieve their maximal effect after 3 months. 30 The most common adverse effects are dry mouth, dry eyes, and constipation. A major concern regarding the use of anticholinergics in male patients is the risk of urinary retention. However, in compared with placebo. 38, 39 It also improves OAB symptoms related to BPH without a substantial difference in postvoid residual volumes. 40 Because this drug has been approved for a short period, many questions about how to best implement its use remain unanswered.
Although monotherapy is sufficient for some men, a combination of treatments may be necessary to achieve maximal therapeutic response. Combination therapy with an α-blocker to rapidly reduce LUTS and an ARI to shrink the prostate can be used. 41 The Medical Therapy of Prostate Symptoms and the Combination Avodart and
Tamsulosin trials showed that the combination of an α-blocker and an ARI inhibitor prevents progression of BPH better than either agent alone. [41] [42] [43] If monotherapy or combination therapy with an α-blocker and an ARI fails to control symptoms to the patient's satisfaction, specialty evaluation is indicated before further treatment. 44 The medical literature supports the use of other combinations of medications for the management of LUTS in specific clinical scenarios. For example, the combination of a PDE5 inhibitor with an α-blocker is significantly more effective than an α-blocker alone in men with LUTS related to BPH. 45 In addition, in men with BPH, a combination of an α-blocker and an anticholinergic can improve quality of life, voiding symptom scores, urinary urgency and frequency, and nocturia better than either agent alone. 46, 47 If combination therapy is unsuccessful, surgical intervention may be necessary. 
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